Context Malaria and sexually transmitted infections/reproductive tract infections (STIs/ RTIs) in pregnancy are direct and indirect causes of stillbirth, prematurity, low birth weight, and maternal and neonatal morbidity and mortality.
T HERE ARE 880 000 STILLBIRTHS 1 and 1.2 million neonatal deaths 2 each year in sub-Saharan Africa. Low birth weight (Ͻ2.5 kg), attributable to intrauterine growth retardation, preterm delivery, or both, is the leading risk factor for neonatal mortality. 3 Intrauterine infection is implicated in stillbirth 4 and is associated with 25% to 40% of preterm births. 5 Sexually transmitted infections and reproductive tract infections (STIs/RTIs) 6 and malaria 7 are associated with adverse birth outcomes, but both may be mitigated with preventive or presumptive treatment or by repeated screening and treatment throughout the antenatal period. The extent to which either approach may be beneficial depends on the underlying prevalence of STIs/RTIs and malaria in pregnancy. This systematic review and meta-analysis provide estimates for the dual prevalence of STIs/RTIs and malaria in pregnancy among women attending antenatal care facilities in sub-Saharan Africa.
METHODS
We searched 3 databases, PubMed, MEDLINE, and EMBASE, in Novem-ber 2011 using Medical Subject Headings and free text terms, respectively; the World Health Organization (WHO) International Clinical Trials Registry; and relevant reference lists to identify studies conducted between 1990-2011 that reported point prevalence estimates for STIs/RTIs, malaria, or both among pregnant women attending antenatal care facilities in sub-Saharan Africa (eAppendix 1; available at http: //www.jama.com). If 2 or more prevalence estimates were reportedwhether the result of a comparative diagnostic study, use of the same diagnostic method on multiple occasions, or subsequent use of a more sensitive assay-we used the higher/highest measurement in our analysis.
Our aim was to establish the dual prevalence of these infections in pregnancy among women receiving antenatal care without inflating estimates by including studies that selectively enrolled women from high-risk groups. Thus, studies that enrolled subsets of women from the antenatal care population were excluded (eg, only pregnant women with human immunodeficiency virus [HIV] ). Studies of commercial sex workers, women seeking treatment at STI facilities or family planning facilities, or nonpregnant women tested in community-based sur-veys were also excluded. Multiyear studies that included pre-1990 data were excluded, as were studies from South Africa, where malaria is no longer endemic.
Records retrieved were all in English, although several abstracts had been translated from Chinese, Danish, Dutch, French, German, Italian, Portuguese, and Swedish. One author (R.M.C.) conducted the data retrieval. Data abstraction was not blinded to author or publication but was performed independently and in duplicate by R.M.C. and a research assistant, reviewing records against inclusion/exclusion criteria to identify 3618 records of interest. Any discrepancies were resolved by D.C. Two authors (P.M. and D.M.) and another researcher assisted R.M.C. in the identification and classification of STI/RTI diagnostic methods; D.C. did the same with R.M.C. for malaria studies. No evidence of publication bias was found using funnel-plot assessment as described by Sterne et al. 8 Given that data for this review have been drawn from studies reporting point preva-lence estimates without intervention, the potential for publication bias should be minimal.
Point prevalences and 95% confidence intervals were calculated for each study. We then applied a standard method 9 for correcting errors of magnitude with the known sensitivity and specificity of individual assays (eAppendix 2 and eAppendix 3) to increase the precision of each point prevalence estimate. Corrected point prevalence data were then used to generate pooled prevalence estimates and corresponding 95% confidence intervals. We stratified results by subregion (East and Southern Africa vs West and Central Africa) because of underlying differences in epidemiology, particularly the extent to which HIV modulates the transmission of malaria and STIs/RTIs.
We conducted the meta-analysis with random-effects models, 10 accounting for the possibility of heterogeneity between studies, and assessed our results with the Q statistic. Separate sensitivity analyses were performed for studies conducted before and after the year 2000 to examine temporal changes in prevalence. Using Stata/IC version 12 software 11 to generate the randomeffects meta-analysis model, we produced forest plots to display the point prevalence and 95% confidence intervals of individual studies as well as the pooled estimates and 95% confidence intervals for all strata.
RESULTS
A total of 171 studies met inclusion criteria, providing 307 point prevalence estimates and including a total of 340 904 women. Search results are summarized in FIGURE 1. The , with key findings reported herein. In all instances, prevalence estimates have been corrected to account for diagnostic errors as previously described.
Syphilis
The pooled mean prevalence of syphilis in East and Southern Africa was 4.5% (95% CI, 3.9%-5.1%), with the highest estimate, 13.7% (95% CI, 9.0%-18.5%), in Vilanculos, Mozambique, based on rapid plasma reagin (RPR) testing and Treponema pallidum hemagglutination confirmation. 12 In West and Central Africa, the pooled mean prevalence of serological syphilis was 3.5% (95% CI, 1.8%-5.2%). Yaoundé, Cameroon, reported the highest point esti-mate of 16.3% (95% CI, 15.2%-17.4%) using a T pallidum hemagglutination assay that confirms syphilis infection, although not necessarily active cases. 13 
Neisseria gonorrhoeae
In East and Southern Africa, the pooled prevalence was 3.7% (95% CI, 2.8%-4.6%), with the highest point estimate of 23.3% (95% CI, 16.4%-30.2%) observed in Manhiça, Mozambique. 12 The pooled mean prevalence of N gonorrhoeae in West and Central Africa was 2.7% (95% CI, 1.7%-3.7%); the highest individual estimate, 4.6% (95% CI, 2.8%-6.3%), came from a study in Abidjan, Cô te d'Ivoire, that used culture diagnostic methods. 14 
Chlamydia trachomatis
The pooled prevalence of C trachomatis infection in East and Southern Africa was 6.9% (95% CI, 5.1%-8.6%), with Khartoum, Sudan, reporting the highest prevalence estimate of 23.2% (95% CI, 16.5%-29.9%) as detected by an enzyme immunoassay. 15 In West and Central Africa, the pooled mean prevalence was 6.1% (95% CI, 4.0%-8.3%). The highest prevalence, 16 .4% (95% CI, 12.6%-20.1%) based on culture or enzyme immunoassay, was observed in Pikine, Senegal. 16 
Trichomonas vaginalis
The pooled prevalence of T vaginalis infection was 29 22 In West and Central Africa, the pooled prevalence was 39.9% (95% CI, 34.2%-45.7%), and the highest point prevalence was 91.6% (95% CI, 84.8%-94.4%) as diagnosed by placental histology, impression, and smears with microscopy in Ebolowa, Cameroon. 23
Dual Prevalence of STIs/RTIs and Malaria
Only 5 publications reported the prevalence of syphilis and malaria, [24] [25] [26] [27] [28] and no single article reported coinfection of malaria and STIs/RTIs. Subanalysis in a prospective cohort study of pregnant women in Tanzania provided some of the only published data on coinfection: 48.3% of RPR-positive women also had placental parasitemia and 35.0% of RPR-negative women had malariainfected placentas (P Ͻ.001). 29 
COMMENT
This systematic review of STIs/RTIs and malaria prevalence estimates over a 20year period suggests that a considerable burden of malaria and STIs/RTIs exists at the population level among pregnant women attending antenatal facilities in sub-Saharan Africa. However, the absence of reports on coinfection makes it impossible to describe the prevalence of malaria only, curable STIs/RTIs only, or coinfection in pregnancy.
The GRADE approach to data quality assessment 30 was considered inappropriate for this particular metaanalysis. It is a useful and transparent tool for the analysis of treatment outcomes following contrasting interventions produced by different study designs. However, because we included studies that had open enrollment in the antenatal care setting and we were not investigating the effect of medical intervention, we did not expect the population prevalence of STIs/RTIs and malaria in pregnancy to vary across study designs. In addition, the GRADE system requires ranking of evidence by outcomes of interest, scored as high, intermediate, low, or very low. In this review, we could have assigned quality scores to point prevalence estimates, but that would have introduced a limited but unavoidable level of subjectivity. Thus, we chose instead to improve the precision of each point estimate with a standard method 9 for correcting errors of known magnitude before incorporating data into the random-effects models. This same approach has been used with prevalence data from Tanzania to compare STI/RTI estimates derived by disparate diagnostic tests. 31 We present corrected and uncorrected point prevalence estimates by study in eTable 1 through eTable 7.
Diagnostic methods and tools have changed for many pathogens during the period covered in this review. The advent of molecular tests such as PCR and ligase chain reaction has allowed researchers in recent years to detect infection where older diagnostic methods may have failed to do so. Although our statistical correction for diagnostic errors can make data more comparable, the pooled mean prevalence of STIs/RTIs and malaria is still probably an underestimate of the true burden of disease. Among 59 studies providing estimates for syphilis prevalence, 45 used the nontreponemal RPR or venereal disease research laboratory tests confirmed by a Treponema-specific test, reflecting wide acceptance of the diagnostic gold standard. Because biological false-positive nontreponemal test results can be produced by malaria and other infections, the burden of syphilis in studies that did not use treponemal confirmatory testing may be overstated.
A variety of diagnostic methods were used for identifying N gonorrhoeae and C trachomatis infections, whereas wetmount microscopy was used in all but 2 studies reporting trichomoniasis prevalence, a method notoriously lacking sensitivity compared with culture or molecular tests. 32, 33 Bacterial vaginosis was diagnosed using 4 methods: Nugent score, Spiegel criteria, Amsel criteria, and clue cell prevalence estimates. The Nugent score 34 is the preferred objective method and was used in studies reporting the 7 highest rates of infection from East and Southern Africa. Thus, the pooled mean prevalence would likely have been higher had the Nugent score been used in all studies.
Peripheral parasitemia may be underrepresented for 2 reasons. Infection tends to be highest between gestational weeks 9 through 16, declining until term. 35, 36 No studies appeared to have measured peripheral parasitemia during this peak period. Another important source of underestimated disease burden is that most malaria diagnoses were based on microscopy without molecular test correction. A study in Blantyre, Malawi, illustrates the extent to which underdiagnosis may occur with conventional microscopy; the prevalence of peripheral parasitemia of 51.9% (95% CI, 43.4%-60.3%) was found by PCR, while microscopy detected infection only in 14.9% (95% CI, 11.8%-18.0%) of pregnant women. 37 The dual prevalence of STIs/RTIs and malaria varied in the subregions we analyzed. Overall, East and Southern Africa has a greater burden of STIs/RTIs compared with West and Central Africa. Several factors that are linked to exposure may contribute to this difference, including higher prevalence of STIs/RTIs circulating at the community level, patterns of male circumcision as well as sexual behavior related to age of sexual debut, age atfirstmarriage,premaritalsex,andnumber of total partners and concurrent sex partners. The prevalence of HIV, for example, remains substantially higher in East and Southern Africa compared with the West and Central subregion. According to the Joint United Nations Programme on HIV/AIDS, 34% of the world's HIV-positive population was living in 10 countries of Southern Africa in 2010. 38 The epidemic in East Africa has declined over the past decade, but HIV prevalence remains higher than in West and Central Africa.
Peripheral and placental malaria is slightly higher in West and Central Africa compared with the East and Southern subregion. This may be due to greater seasonal variation in transmission within West and Central Africa. Recent declines in malaria transmission within selected locales of Africa will likely translate into fewer pregnant women acquiring immunity from one pregnancy to the next. Thus, all women in their reproductive years (rather than just those in their first or second pregnancies) may remain vulnerable to malaria in the years ahead until the absolute risk of exposure is negligible.
Human immunodeficiency virus and malaria interact to increase parasitic infection of the placenta and incidence of low birth weight. 39 Plasmodium falciparum infection also increases viral load among HIV-positive pregnancy women. 40 New evidence suggests that malaria parasites are more likely to develop wildtype mutations following exposure to sulfadoxine-pyrimethamine as intermittent preventive treatment during pregnancy (IPTp) when administered to HIVpositive women. 41 The interaction between STIs/RTIs and HIV has been well established, although providing presumptive treatment for STIs/RTIs to pregnant women in Rakai, Uganda, has not shown protective effect against maternal to child transmission of HIV. 42 However, malaria chemoprophylaxis was not provided in this study; therefore, the potential modulating effect of malaria on maternal to child transmission in the presence of STIs/RTIs remains unknown.
Our study has several limitations. An unavoidable but important limitation is the inherent delay between gathering evidence at the clinic level and public dissemination. This is important in our study because HIV prevention campaigns, including STI/RTI screening and treatment programs, have made inroads in reducing transmission in many settings. To capture these reductions with greater precision, more recent data are needed. Another limitation is that even after stratifying by geography and age of study, heterogeneity among studies persisted. The random-effects models, in turn, produced wide 95% confidence intervals in some instances. In addition, because we relied on evidence from English-language sources and abstracts that had been translated into English, we may have identified fewer studies from researchers who publish in other languages.
There is a major risk of adverse birth outcomes associated with malaria and STIs/RTIsinpregnancy.Morethan30million pregnant women are at risk of infectioneachyearinsub-SaharanAfrica. 43 Malariaisassociatedwithintrauterinegrowth retardation, preterm delivery, low birth weight, 44,45 stillbirth, 44 early neonatal death, 44 and maternal anemia. 45 In Tanzania, T pallidum is associated with 51% of stillbirths and 24% of preterm live births. 46 Neisseria gonorrhoeae is associated with a 2-fold increase in the risk of preterm delivery, 47 whereas the risk of early preterm delivery in the presence of Ctrachomatisinfectionis4timeshigher. 48 Untreated C trachomatis infects the eyes of50%ofnewbornsatdelivery,andpneu-moniawilldevelopin10%to20%ofthese infants. 49, 50 Neisseria gonorrhoeae and C trachomatis are common causes of ophthalmia neonatorum and may lead to corneal scarring and blindness if untreated. Trichomonas vaginalis infection is associated with a 2-fold increase in preterm delivery, 51 asisbacterialvaginosis,theodds of which are 7 times higher when the condition manifests prior to 16 weeks' gestation. 52 Bacterial vaginosis is also significantlyassociatedwiththeriskofspontaneous abortion. 52 Within this context, progress toward the maternal and child healthtargetsofMillenniumDevelopment Goals may be possible by improving ma-lariaandSTI/RTIcontrolmeasureswithin the antenatal care package.
Several current infection control strategies are included in the antenatal care package. In areas of stable malaria transmission, WHO recommends that pregnant women sleep under insecticidetreated mosquito bed nets and receive 2 to 3 treatment courses of SP-IPTp during antenatal consultations. Drug resistance to SP has compromised the protective effect of SP-IPTp in recent years, prompting a need to identify efficacious drugs and new strategies to prevent malaria in pregnancy. 53 WHO recommends syphilis screening and treatment for pregnant women at their first antenatal visit. For other curable STIs/RTIs, WHO suggests using syndrome-based algorithms to guide diagnosis and treatment. However, the vast majority of gonococcal (80%) and chlamydial (70%-75%) infections in women are asymptomatic 54 and therefore never diagnosed. Consequently, the algorithm based on vaginal discharge syndrome has a low sensitivity (30%-80%) and specificity (40%-80%) for N gonorrhoeae and C trachomatis among pregnant women. [55] [56] [57] Syndromic management has slightly higher sensitivity for T vaginalis (54%-83%) and bacterial vaginosis (51%-69%), with moderate specificity (40%-54% for T vaginalis and 40%-58% for bacterial vaginosis). 58 In addition, potential new directions for the antenatal care package have been suggested, including use of novel drugs and rapid diagnostic tests. Several trials ofazithromycin-basedcombinationtherapies are under investigation for use in IPTp. Azithromycin has modest antimalarial properties but needs a partner antimalarial drug against P falciparum. 59 Despite concerns about drug resistance, 60 a 2-g dose of azithromycin has resulted in cure rates of 97.7% (95% CI, 94.0%-99.4%) of syphilis cases in a study in Tanzania. 61 A single 2-g dose of azithromycin was 98.9% (95% CI, 97.9%-100%) efficacious against N gonorrhoeae in the United States, 62 while meta-analysis showed that 1 g cures 96.5% (95% CI, 95.3%-97.7%) of C trachomatis infections. 63 A trial in Malawi using 1 g of azithromycinadministeredtwicewithSP-IPTp reduced the risk of T vaginalis 35% (P=.02). 64 Azithromycin-basedcombinations could protect against bacterial vaginosis if administered early in pregnancy; a meta-analysis of antibiotic therapy for thetreatmentofbacterialvaginosisinpregnancy prior to gestational week 20 is associatedwithasignificantreductioninthe risk of preterm birth. 65 Novel use of rapid diagnostic tests may replace IPTp with sulfadoxinepyrimethamine altogether if used for intermittentscreeningandtreatmentformalaria during antenatal visits. Intermittent screening and treatment with artesunate-amodiaquinewasnoninferiortoIPTpwith sulfadoxine-pyrimethamine in Ghana in anareawheresulfadoxine-pyrimethamine resistance was low; the incidence of low birthweightwassimilarbetweentheIPTp with sulfadoxine-pyrimethamine and intermittentscreeningandtreatmentgroups among multigravid mothers (11.3% vs 11.3%) and among primigravid mothers (16.1% vs 17.2%). 66 Rapid point-of-care tests for HIV have revolutionized the uptake and performance of voluntary counseling and testing 67 and are used in some antenatal settings in Africa. Point-of-care testsforsyphilisareincreasinglyavailable, making possible same-day results and prompt treatment. 68, 69 Mitigating the dual prevalence of malaria and STIs/RTIs will require improvements in the Safe Motherhood package. 70 Bacterial vaginosis requires particular at-tention given its high prevalence. Clinical trials are needed to investigate the protective effect of presumptive treatment of bacterial vaginosis with metronidazole at time points that are biologically optimal and operationally feasible. It is less clear whether pregnancy outcomes would be improved more with point-of-care tests and treatment for HIV, syphilis, and malaria,whilesyndromicmanagementisprovided for the remaining curable STIs/ RTIs-or if maternal, fetal, and newborn health will be better if women are given point-of-care tests for HIV and syphilis along with azithromycin-based combination therapy in IPTp. Rigorously conducted clinical trials are urgently needed.
CONCLUSION
The dual prevalence of malaria and STIs/RTIs is evident among pregnant women who attend antenatal facilities in sub-Saharan Africa. As malaria control and elimination efforts are brought to scale, the relative contribution of STIs/RTIs to adverse birth outcomes most likely will increase proportionately. Coinfection prevalence estimates for malaria and STIs/RTIs need to be established and routinely reported. Rigorous studies using molecular diagnostic methods are needed to characterize more accurately the prevalence of these infections and their clinical consequences. Clinical trials are needed to compare birth outcomes, operational feasibility/acceptability, and cost-effectiveness of IPTp with azithromycin-based combination therapy against an approach of integrated screening and treatment for malaria and STIs/RTIs. 
